Netherlands· NL-09cd7ab84481
Tibsovo 250 mg, filmomhulde tabletten
A medicinal product containing ivosidenib, registered in Netherlands by Les Laboratoires Servier.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- IVOSIDENIB
- Manufacturer
- Les Laboratoires Servier
- Country
- Netherlands (NL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/23/1728
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ivosidenib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTibsovo 250 mgLes Laboratoires Servier
- SwitzerlandTibsovo 250 mg, comprimés pelliculésServier (Suisse) SA
- CzechiaTIBSOVOLes Laboratoires Servier, Suresnes cedex
- SpainTIBSOVO 250 MG COMPRIMIDOS RECUBIERTOS CON PELICULALes Laboratoires Servier
- FinlandTibsovoLes Laboratoires Servier
- FranceTIBSOVO 250 mg, comprimé pelliculéLES LABORATOIRES SERVIER
- IrelandTibsovo 250 mg Film-coated tabletLes Laboratoires Servier
- IcelandTibsovoLes Laboratoires Servier*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tibsovo
- Liechtenstein · Tibsovo
- Norway · Tibsovo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/89324cee-7b9f-4079-9683-b54af7f4dff0 GET /v1/drugs/89324cee-7b9f-4079-9683-b54af7f4dff0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmomhulde tablet",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_nl.pdf",
"strength": null,
"atc_label": null,
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129756",
"excipients": [
"CELLULOSE, MICROKRISTALLIJN (E 460(i))",
"CROSCARMELLOSE NATRIUM (E 468)",
"GLYCEROLTRIACETAAT (E 1518)",
"HYPROMELLOSE (E 464)",
"HYPROMELLOSEACETAATSUCCINAAT",
"INDIGOKARMIJN ALUMINIUMLAK (E 132)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMLAURILSULFAAT",
"SILICIUMDIOXIDE (E 551)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"IVOSIDENIB"
],
"leaflet_url": null,
"authorised_at": "2023/05/04",
"procedure_number": "EMEA/H/C/005936",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/23/1728",
"additional_monitoring": "Y"
}See everything about ivosidenib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.